Astrazeneca plc ADR (NASDAQ:AZN)’s traded shares stood at 1.62 million during the latest session, with the company’s beta value hitting 0.47. At the last check today, the stock’s price was $66.16, to imply a decrease of -0.54% or -$0.36 in intraday trading. The AZN share’s 52-week high remains $87.68, putting it -32.53% down since that peak but still an impressive 8.6% since price per share fell to its 52-week low of $60.47. The company has a valuation of $205.14B, with an average of 5.73 million shares in intraday trading volume over the past 10 days and average of 5.65 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Astrazeneca plc ADR (AZN), translating to a mean rating of 1.50. Of 10 analyst(s) looking at the stock, 0 analyst(s) give AZN a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 8 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 1.1.
Astrazeneca plc ADR (NASDAQ:AZN) trade information
After registering a -0.54% downside in the latest session, Astrazeneca plc ADR (AZN) has traded red over the past five days. The 5-day price performance for the stock is 2.67%, and -0.30% over 30 days. With these gigs, the year-to-date price performance is -1.77%. Short interest in Astrazeneca plc ADR (NASDAQ:AZN) saw shorts transact 7.4 million shares and set a 0.92 days time to cover.
The extremes give us $88 and $88 for target low and target high price respectively. As such, AZN has been trading -33.01% off suggested target high and -33.01% from its likely low.
Astrazeneca plc ADR (AZN) estimates and forecasts
Looking at statistics comparing Astrazeneca plc ADR share performance against respective industry, we note that the company has outperformed competitors. Astrazeneca plc ADR (AZN) shares are -15.17% down over the last 6 months, with its year-to-date growth rate higher than industry average at 13.22% against 8.20%. The rating firms project that company’s revenue will grow 15.93% compared to the previous financial year.
Revenue forecast for the current quarter as set by 8 analysts is 14.24B. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 13.54B.Earnings reports from the last fiscal year show that sales brought in 12.02B and 12.68B respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 18.41% before jumping 6.75% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 17.72% for the past 5-year period. While 2024 is set for a 13.74% return in earnings, projections for the next 5 years are at 12.00% annually.
AZN Dividends
Astrazeneca plc ADR has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Astrazeneca plc ADR has a forward dividend ratio of 1.48, with the share yield ticking at 2.24% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 2.35%.
Astrazeneca plc ADR (NASDAQ:AZN)’s Major holders
Astrazeneca plc ADR insiders hold 0.01% of total outstanding shares, with institutional holders owning 16.76% of the shares at 16.76% float percentage. In total, 16.76% institutions holds shares in the company, led by PRICE T ROWE ASSOCIATES INC /MD/. As of 2024-06-30, the company held over 64.94 million shares (or 2.0962% of shares), all amounting to roughly $5.06 billion.
The next major institution holding the largest number of shares is PRIMECAP MANAGEMENT CO/CA/ with 42.6 million shares, or about 1.375% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $3.32 billion.
